The development-stage pharmaceutical company Transpire Bio has announced a definitive agreement with Recipharm to develop TRB-1 and TRB-2, inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).
TRB-1 and TRB-2, the first products developed by Transpire Bio will be indicated for the treatment of asthma and COPD, intended for advanced markets.
“Recipharm is very pleased to be leveraging its broad experience and expertise in developing and commercializing inhalation technologies and products in support of the development and advancement of Transpire Bio’s TRB-1 and TRB-2 respiratory products. We look forward to the collaboration,” says Jean-Francois Hilaire, Executive Committee Member, Head of Business Unit Advanced Delivery Systems Recipharm.
Photo: Recipharm
